AbbVie (NYSE:ABBV) shares snapped eight consecutive sessions of losses as the stock closed up 0.78% at $166.28. The North ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
Zacks.com on MSN3d
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
7don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Zacks.com on MSN22h
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in EuropeThe EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback